Off-the-shelf natural killer cells to target solid tumours in clinical trial
Immunotherapy has improved treatments melanoma, but many tumours can evade the immune system.
UC San Diego and Fate Therapeutics are running a clinical trial with natural killer cells.
Natural killer (NK) cells are specialized white blood cells able to break through cell membranes.
Targeting people with advanced solid tumours with off-the-shelf NK cells.
First trial in the U.S. to use cells derived from induced pluripotent stem (iPS) cells.
Dr. Dan Kaufman developed a method of expanding large numbers of NK cells in 2013.
Preclinical research demonstrated effective killing of cancer cells in cell culture and in mouse models.
Phase I trial started in February and will include up to 64 people with advanced, untreatable cancer.
Will test on their own as well as in combination with a checkpoint inhibitor.